Clinical Scorecard: Higher-Volume Injections Don’t Elevate Glaucoma Risk
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma risk associated with higher-volume intravitreal injections |
| Key Mechanisms | Analysis of intraocular pressure (IOP) stability with higher-volume agents |
| Target Population | Treatment-naïve patients receiving intravitreal therapies |
| Care Setting | Real-world clinical practice |
Key Highlights
- No significant IOP elevation or glaucoma risk with aflibercept 8 mg, pegcetacoplan, or avacincaptad pegol.
- Mean IOP remained stable within 1 mmHg of baseline across all treatment groups.
- Study analyzed data from 3,741 eyes with strict inclusion/exclusion criteria.
- No statistically significant increase in glaucoma incidence compared to control groups.
- Real-world data corroborate findings from phase 3 clinical trials.
Guideline-Based Recommendations
Diagnosis
- Monitor IOP in patients receiving higher-volume intravitreal injections.
Management
- Continue using higher-volume agents as they do not increase glaucoma risk.
Monitoring & Follow-up
- Longitudinal follow-up is necessary to ensure ongoing safety of higher-volume therapies.
Risks
- Isolated finding of statistically significant risk of IOP elevation with pegcetacoplan compared to control.
Patient & Prescribing Data
Patients with neovascular age-related macular degeneration and diabetic macular edema, as well as geographic atrophy.
Aflibercept 8 mg often used with a treat-and-extend regimen; PEG and ACP administered at fixed intervals.
Clinical Best Practices
- Ensure strict patient selection criteria to exclude those with prior ocular trauma or glaucoma.
- Utilize real-world data to inform treatment decisions and patient monitoring.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.